LEXAPRO
Drug
ABBVIE INC.
Total Payments
$376,358
Transactions
94
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $1,500 | 1 | 0 |
| 2022 | $374,858 | 93 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $376,344 | 92 | 100.0% |
| Education | $13.92 | 2 | 0.0% |
Payments by Type
Research
$376,344
92 transactions
General
$13.92
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder | ABBVIE INC. | $376,344 | 0 |
Top Doctors Receiving Payments for LEXAPRO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $376,344 | 92 |
| , M.D | Psychiatry | Huntersville, NC | $13.92 | 2 |
Ad
Manufacturing Companies
- ABBVIE INC. $376,358
Product Information
- Type Drug
- Total Payments $376,358
- Total Doctors 1
- Transactions 94
About LEXAPRO
LEXAPRO is a drug associated with $376,358 in payments to 1 healthcare providers, recorded across 94 transactions in the CMS Open Payments database. The primary manufacturer is ABBVIE INC..
Payment data is available from 2022 to 2023. In 2023, $1,500 was paid across 1 transactions to 0 doctors.
The most common payment nature for LEXAPRO is "Unspecified" ($376,344, 100.0% of total).
LEXAPRO is associated with 1 research study, including "A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder" ($376,344).